bluebird bio (BLUE) PT Raised to $83 at BMO as bb2121 Shows Promising Efficacy, Clean Safety
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/19/2024
- Nasdaq, S&P tumble as Netflix, chip stocks drag; AmEx boosts Dow
- Sony/Apollo bid for Paramount could be worth as much as $29 billion - Source
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Nasdaq tumbles, Treasuries dip amid earnings, geopolitical crosscurrents
- Gold prices rally past $2,400 on reports of Israel strikes on Iran
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Jabil falls after placing CEO on paid leave amid internal investigation
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- Ibotta (IBTA) Prices 6.56M Share IPO at $88/sh
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
bluebird bio (BLUE) PT Raised to $87 at Maxim Group
December 1, 2016 11:45 AM ESTMaxim Group analyst Jason McCarthy reiterated a Buy rating and lifted his price target on bluebird bio (NASDAQ: BLUE) to $87.00 (from $57.00) following early positive data in Multiple Myeloma.
McCarthy highlighted:
bluebird announced (early) positive data in Multiple Myeloma. The phase 1 study of bb2121 CAR-T, targeting BCMA (B Cell Maturation Antigen) in relapsed/refractory multiple myeloma (r/r MM) treated 11 patients with escalating doses of bb2121. In 9 evaluable patients there was an overall... Morebluebird bio (BLUE) PT Raised to $85 at Leerink Partners
December 1, 2016 11:26 AM ESTLeerink Partners analyst Michael Schmidt reiterated an Outperform rating and lowered his price target on bluebird bio (NASDAQ: BLUE) to $85.00 (from $80.00) amid higher confidence in bb2121 for Myeloma.
Schmidt commented, "We are increasing our Price Target (PT) on BLUE shares to $85 from $80... More
bluebird bio (BLUE) PT Raised 10% at Jefferies Following 'Impressive' Initial BCMA CAR-T Ph1 Data
December 1, 2016 7:47 AM ESTJefferies analyst Gena Wang reiterated a Buy rating and lifted her price target on bluebird bio (NASDAQ: BLUE) to $88.00 (from $80.00) following 'impressive' initial BCMA CAR-T Ph1 data at ENA.
Wang commented, "BLUE/CELGs anti-BCMA CAR T cells (bb2121) showed promising initial... More
bluebird bio (BLUE) Reports Interim Phase 1 Dose Escalation Data for its Anti-BCMA CAR T Product Candidate
November 30, 2016 5:28 PM ESTbluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, announced that interim data from its ongoing Phase 1 clinical study of bb2121, the companys investigational anti-BCMA CAR T cell product candidate in patients with relapsed/refractory multiple myeloma, will be presented on Thursday, December 1, 2016 at the 28th... More
